Psoriasis Clinical Trial
Official title:
Digital Imaging as a Tool for Assessing the Prevalence of Atypical Nevi, Psoriasis and Hand Dermatitis: A Validation Study in Preparation for NHANES IV, Dermatology Section
This study will evaluate whether digital photography is a reliable tool for diagnosing hand
rashes, psoriasis and unusual moles. The findings will help determine if this method can be
used in the National Health and Nutrition Examination survey (NHANES), which monitors
disease in the United States.
Employees of the National Institutes of Health 19 years and older may enroll in this study.
Participants will complete a brief questionnaire that includes information on skin type,
history of skin conditions (moles, cancer, rashes, psoriasis), and demographic information
such as name, age and sex. They will be examined by a dermatologist, who will note in
writing the appearance of any hand rashes, unusual moles, or psoriasis. If any areas
suspicious for skin cancer are found, the participant will receive this information in
writing, along with advice about where to go for treatment.
A total of six photographs will then be taken of the participant's arms, legs, hands and
back. The face will not be photographed, and the participants will not be identifiable.
This validation study is designed to evaluate the sensitivity, specificity, validity and
reliability of digital photography of the skin as a prevalence assessment tool in
preparation for the National Health and Nutrition Examination Survey, 2001 (NHANES IV).
NHANES is charged with monitoring disease in the U.S. population, which is affected
frequently by skin disorders and disease. The three skin disorders proposed for study in
NHANES IV are atypical nevi, psoriasis, and hand dermatitis. This selection is based on the
expected impact of these diseases on the U.S. population, including a prevalence of 3-10%,
associated risk of melanoma in the case of atypical nevi, and associated disability in the
cases of psoriasis and hand dermatitis.
This skin disease section of NHANES, as currently planned for 2001, includes an imaging
component with four standardized photographs to be obtained from each survey participant
(SP). The selection of the regions to be photographed is designed to maximize the
information obtained, while preserving patient privacy and is based on the known
distribution of clinical findings of the three conditions, as well as NHANES logistical
limitations. This validation study is a cooperative effort between the NIAMS extramural
programs, the NCI intramural program, and the National Center for Health Statistics.
;
N/A
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03236870 -
A Study to Evaluate the Effectiveness and Patient-Reported Outcome of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in China
|
||
Completed |
NCT00078819 -
Etanercept (Enbrel®) in Psoriasis - Pediatrics
|
Phase 3 | |
Completed |
NCT04841187 -
Assessing the Long Term Effectiveness and Safety of Systemic Treatments in Cutaneous Psoriasis
|
||
Active, not recruiting |
NCT03927352 -
The Purpose of This Research Study is to Compare the Efficacy and Safety of SCT630 and Adalimumab (HUMIRA®) in Adults With Plaque Psoriasis
|
Phase 3 | |
Completed |
NCT03284879 -
Post-Marketing Surveillance Study of OTEZLA
|
||
Recruiting |
NCT06027034 -
Effectiveness of a Digital Health Application for Psoriasis
|
N/A | |
Not yet recruiting |
NCT06050330 -
CD4+ T Cells and S100A7 Epression in Normal and Psoriatic Skin: A Histological and Histochemical Study
|
N/A | |
Recruiting |
NCT05744466 -
A Real-world Observational Study to Compare Effectiveness of Deucravacitinib Vs Apremilast in Adults With Plaque Psoriasis
|
||
Completed |
NCT04149587 -
A Study of Brodalumab (SILIQ®) in Psoriasis Participants With Inadequate Response to Their Current Biologic Agent Regimen
|
||
Completed |
NCT01384630 -
Safety, Pharmacokinetics, and Efficacy of RA-18C3 in Subjects With Moderate to Severe Psoriasis
|
Phase 2 | |
Completed |
NCT03998683 -
A Study of Guselkumab for the Treatment of Palmoplantar-non-Pustular Psoriasis
|
Phase 3 | |
Terminated |
NCT03556202 -
A Long-term Study to Evaluate Safety and Maintenance of Treatment Effect of LY3074828 in Participants With Moderate-to-Severe Plaque Psoriasis (OASIS-3)
|
Phase 3 | |
Completed |
NCT05051943 -
A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
|
||
Recruiting |
NCT06077331 -
A Study to Evaluate Efficacy and Safety of HS-10374 for Moderate to Severe Plaque Psoriasis
|
Phase 2 | |
Completed |
NCT04316585 -
A Study to Evaluate the Benefit and Safety of GSK2982772 in Moderate to Severe Psoriasis Participants
|
Phase 1 | |
Completed |
NCT04894890 -
A Prospective Multicenter Study for the Assessment of Treatment Patterns, Effectiveness and Safety of Secukinumab in Adult Patients With Moderate to Severe Plaque Psoriasis in a Real-world Setting in China
|
||
Completed |
NCT00358384 -
Chronic Plaque Psoriasis Study With Topical Formulation Of GW786034
|
Phase 1 | |
Completed |
NCT03757013 -
A Study to Assess Benefits of Apremilast in Patients With Moderate to Severe Chronic Plaque Psoriasis Followed by Dermatologists Under Real Life Settings in France
|
||
Completed |
NCT03265613 -
Safety and Efficacy of Expanded Allogeneic AD-MSCs in Patients With Moderate to Severe Psoriasis
|
Phase 1/Phase 2 | |
Completed |
NCT05003531 -
A Study to Evaluate IBI112 in the Treatment of Subjects With Moderate to Severe Plaque Psoriasis
|
Phase 2 |